MENU
+Compare
EBS
Stock ticker: NYSE
AS OF
Jan 17 closing price
Price
$9.88
Change
-$0.09 (-0.90%)
Capitalization
120.07M

EBS Emergent Biosolutions Forecast, Technical & Fundamental Analysis

a manufacturer of biopharmaceutical products

EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for EBS with price predictions
Jan 08, 2025

EBS in -8.30% downward trend, falling for three consecutive days on December 19, 2024

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where EBS declined for three days, in of 309 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for EBS moved out of overbought territory on January 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

EBS broke above its upper Bollinger Band on December 30, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for EBS entered a downward trend on January 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 30, 2024. You may want to consider a long position or call options on EBS as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EBS just turned positive on December 30, 2024. Looking at past instances where EBS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

EBS moved above its 50-day moving average on December 30, 2024 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for EBS crossed bullishly above the 50-day moving average on January 07, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EBS advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EBS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.185) is normal, around the industry mean (58.527). P/E Ratio (17.730) is within average values for comparable stocks, (90.460). EBS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.947). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (0.115) is also within normal values, averaging (19.547).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

EBS is expected to report earnings to fall 129.93% to -40 cents per share on February 20

Emergent Biosolutions EBS Stock Earnings Reports
Q4'24
Est.
$-0.41
Q3'24
Beat
by $1.27
Q2'24
Missed
by $1.37
Q1'24
Beat
by $1.42
Q4'23
Missed
by $0.58
The last earnings report on November 06 showed earnings per share of $1.37, beating the estimate of 10 cents. With 872.63K shares outstanding, the current market capitalization sits at 120.07M.
A.I. Advisor
published General Information

General Information

a manufacturer of biopharmaceutical products

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
300 Professional Drive
Phone
+1 240 631-3200
Employees
1600
Web
https://www.emergentbiosolutions.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAGFF0.35N/A
+0.71%
Aftermath Silver Ltd.
ISUZY13.21-0.02
-0.15%
Isuzu Motors, Ltd.
NTTYY24.22-0.23
-0.94%
Nippon Telegraph & Telephone Corp.
VWSYF13.08-0.19
-1.43%
Vestas Wind Systems A/S
TNEYF3.21-0.08
-2.57%
Tamarack Valley Energy, Ltd.

EBS and Stocks

Correlation & Price change

A.I.dvisor tells us that EBS and AMRX have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EBS and AMRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-0.90%
AMRX - EBS
29%
Poorly correlated
-0.60%
ZOM - EBS
29%
Poorly correlated
+2.53%
SNDL - EBS
27%
Poorly correlated
-1.11%
ACET - EBS
27%
Poorly correlated
-1.22%
HROW - EBS
26%
Poorly correlated
+1.17%
More